Anish Rawat

Learn More
Purpose: To assess the activity and toxicity of interferon-α (IFN-α), capecitabine, and thalidomide in patients with metastatic renal cell carcinoma (MRCC). Patients and methods: Twenty-seven patients were enrolled in a pilot study to receive oral capecitabine 1,900 mg/m2/day in 2 daily doses, 2 weeks on, l week off; daily subcutaneous IFN-α 1 mIU without(More)
BACKGROUND The purpose of the study was to determine, in a Phase I/II study, the efficacy and safety profile of thalidomide with interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC). METHODS Fifteen patients (8 of whom were previously treated) enrolled in Phase I were treated with escalating doses of oral thalidomide (200-600 mg)(More)
PURPOSE To assess the activity and toxicity of interferon-alpha (IFN-alpha), capecitabine, and thalidomide in patients with metastatic renal cell carcinoma (MRCC). PATIENTS AND METHODS Twenty-seven patients were enrolled in a pilot study to receive oral capecitabine 1,900 mg/m2/day in 2 daily doses, 2 weeks on, l week off; daily subcutaneous IFN-alpha 1(More)
OBJECTIVE The early efficacy and safety findings observed with thalidomide plus low-dose Interleukin-2 (IL-2) combination therapy for the treatment of metastatic renal cell carcinoma (MRCC) formed the foundation for this study. Granulocyte macrophage-colony stimulating factor (GM-CSF) is an important cytokine for priming cellular immune responses. This(More)
Endovascular removal of intravascular thrombus using the AngioJet rheolytic thrombectomy (RT) system has been shown to be clinically effective. This system also permits the concomitant infusion of thrombolytic agent followed by thrombectomy, thus creating a novel strategy known as pharmacomechanical thrombectomy (PMT). Although these interventions have(More)
BACKGROUND Primary central nervous system (CNS) lymphoma is being increasingly recognized in immunosuppressed as well as immunocompetent individuals. It has a poor prognosis and the majority of these have diffuse large B-cell type of morphology. AIM To categorize cases of primary CNS lymphoma according to the International Extranodal Lymphoma Study Group(More)
BACKGROUND Obesity has become a worldwide epidemic and is associated with significant morbidity and mortality. Many strategies to promote weight loss, including medications and surgical techniques, have been developed; however, few have proven effective. As the rates of obesity and associated complications continue to climb, there is growing pressure on the(More)
4702 Background: Thalidomide's anti-RCC activity, the potential that its immunomodulatory and anti-angiogenic effects may augment the antitumor activity of IL-2, and the promising early efficacy and safety findings observed with the combination of low dose sc IL-2 plus thalidomide therapy in the treatment of patients with metastatic RCC (ASCO, 2003) form(More)
4761 Background: Immunomodulatory drugs are a series of compounds that have originated via the deliberate structural modification of thalidomide. CC-5013 is a derivative with enhanced immunological and anti-angiogenic properties without the toxicity associated with the parent compound. Objectives were to determine response, rate time to progression,(More)
  • 1